Mar 15, 2022 | Shareholder Investigations
Natera Loses False Advertising Trial; Natera Stock Drops Significantly on Short Seller Report – Securities Investigation on Behalf of Natera Shareholders.
Kehoe Law Firm, P.C. is investigating whether Natera, Inc. (“Natera or the “Company”) (NASDAQ: NTRA) violated federal securities laws.
IF YOU INVESTED IN NATERA STOCK AND SUFFERED FINANCIAL LOSSES, PLEASE CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS OF YOUR NATERA STOCK HOLDINGS.
On March 15, 2022, before the market opened, CareDX, Inc. announced that it won its false advertising case against Natera.
On this news shares of Natera, Inc. stock fell 12% in premarket trading on March 15, 2022.
On March 9, 2022, Hindenburg Research published a short report addressing Natera, entitled “Natera: Pioneers In Deceptive Medical Billing.” Among other allegations, Natera stated that “[b]ased on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online complaints, FOIA requests to state Medicaid offices and state Attorneys General, and the company’s financial filings, we show how Natera’s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers.”
Following publication of the Hindenburg Research report, Natera’s stock price fell $17.95 per share, or 32.79%, to close at $36.80 per share on March 9, 2022.
Mar 10, 2022 | Shareholder Investigations
MoneyLion Stockholders – Securities Investigation on Behalf of MoneyLion Investors – MoneyLion Shareholders With Losses Greater Than $25,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating whether MoneyLion, Inc. (“MoneyLion” or the “Company”) (NYSE: ML) violated federal securities laws.
MONEYLION INVESTORS WHO HAVE SUFFERED FINANCIAL LOSSES GREATER THAN $25,000 ARE ENCOURAGED TO CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS ABOUT THEIR MONEYLION SECURITIES.
On March 10, 2022, MoneyLion reported, among other things, that “. . . management has noted errors related to operating expenses, net loss and basic and diluted earnings (loss) per share in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and additional paid-in capital and retained earnings in the condensed consolidated balance sheet as of September 30, 2021, along with related impacts to the condensed consolidated statement of cash flows for the nine months ended September 30, 2021 and the condensed consolidated statements of redeemable convertible preferred stock, redeemable noncontrolling interests and stockholders’ deficit for the three and nine months ended September 30, 2021.”
The Company also stated that “[r]elatedly, any press releases, earnings releases, investor presentations or other communications describing the Company’s Original Financial Statements for the Affected Period should no longer be relied upon.”
On this news, during intraday trading on March 10, 2022, MoneyLion’s stock price dropped significantly.
Mar 7, 2022 | Shareholder Investigations
Rivian Stockholders Encouraged to Contact Kehoe Law Firm, P.C. Purchasers of Rivian Securities Pursuant to the Company’s IPO in November 2021 May Have Legal Claims.
Kehoe Law Firm, P.C. is investigating whether Rivian Automotive, Inc. (“Rivian” or the “Company”) (NASDAQ: RIVN) violated federal securities laws.
IF YOU PURCHASED RIVIAN STOCK PURSUANT OR TRACEABLE TO THE COMPANY’S INITIAL PUBLIC OFFERING (“IPO”) ON NOVEMBER 10, 2021 AND SUFFERED LOSSES, PLEASE CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS ABOUT YOUR RIVIAN SECURITIES.
On March 7, 2022, a securities class action lawsuit was filed against Rivian and other defendants in United States District Court, Central District of California. According to the class action complaint, the Registration Statement and Prospectus used to effectuate Rivian’s IPO contained untrue statements of material fact, and omitted information necessary to make the statements made therein not misleading, as well as omitted material facts required to be stated therein.
According to the complaint, the Registration Statement misled investors with respect to the potential for significant reputational damage and cancellation of fully refundable preorders for its R1T and R1S Electric Vehicles due to the Company’s need to address its underpriced Electric Vehicles by raising prices shortly after the IPO.
Rivian investors who purchased, or otherwise acquired, their Rivian securities pursuant or traceable to the Company’s November 2021 IPO are encouraged to contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.
Mar 3, 2022 | Shareholder Investigations
Core Scientific Stock – Core Scientific Shareholders With Losses Greater Than $25,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is conducting a securities investigation to determine whether Core Scientific, Inc. (“Core Scientific” or the “Company”) (NASDAQ: CORZ) violated federal securities laws.
IF YOU INVESTED IN CORE SCIENTIFIC STOCK AND SUFFERED LOSSES GREATER THAN $25,000, PLEASE CLICK HERE TO ACCESS KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE TO PROVIDE DETAILS ABOUT YOUR CORZ STOCK LOSSES.
On March 3, 2022, Seeking Alpha reported (“Crypto miner Core Scientific drops after new short call from Culper Research”) that Core Scientific’s stock price “fell 3.8% after a new short report from Culper Research,” which “alleges that Core Scientific ‘wildly oversold’ both its mining and hosting business. Culper also highlighted that CORZ on Monday disclosed that its board waived a 180-lockup on over 282M shares, which will allow insiders to sell the shares.”
Core Scientific investors with losses greater than $25,000 are also encouraged to contact Kehoe Law Firm, P.C., John Kehoe, Esq., (215) 792-6676, Ext. 801, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.
Mar 1, 2022 | Shareholder Investigations
Securities Fraud Investigation – Verra Mobility Stockholders With Losses Greater Than $25,000 Encouraged To Contact Kehoe Law Firm, P.C. To Discuss Potential Legal Claims.
Kehoe Law Firm, P.C. is conducting a securities investigation to determine whether Verra Mobility Corporation (“Verra Mobility” or the “Company”) (NASDAQ: VRRM) violated federal securities laws.
On February 28, 2022, Verra Mobility announced that it filed a notice of late filing with the SEC, because it will not be able to file its Form 10-K for the year ended December 31, 2021 by the due date of March 1, 2022, and the Company is not expected to do so within the allowable 15-day extension period.
Further, Verra Mobility announced that “[d]uring its year-end 2021 financial statement review process, Verra Mobility . . . determined that revenues from the Company’s recently acquired Australian subsidiary, Redflex Holdings Limited, may not have been recorded in accordance with generally accepted accounting principles. The Company’s Audit Committee is conducting an investigation of the circumstances surrounding these issues to determine, among other things, whether any related adjustment is necessary for the previously issued financial statements for the second and third quarters of fiscal year 2021.”
On this news, Verra Mobility’s stock dropped as much as 7.6% during intraday trading on February 28, 2022, thereby injuring investors.
If you invested in Verra Mobility stock and suffered losses greater than $25,000, please CLICK HERE to provide information about your Verra Mobility stock losses.
Feb 28, 2022 | Shareholder Investigations
Have You Held Evolus Stock Since May 20, 2019? Evolus Investors May Have Legal Claims Against The Company’s Officers and Directors.
Kehoe Law Firm, P.C. is investigating whether the board of directors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) breached their fiduciary duties to Evolus and its stockholders.
An amended securities fraud complaint was filed on behalf of investors who purchased Evolus common stock between February 1, 2019 and July 6, 2020, both dates inclusive (the “Class Period”) and who held such shares on March 4, 2019, and/or March 4, 2020 and/or July 6, 2020 and suffered compensable damages thereby (the “Class”).
The amended compliant alleges, among other things, that Evolus made materially false and misleading statements about its injectible botulinum neurotoxin product Jeuveau, which is used to treat wrinkles.
On July 6, 2020, the Initial Final Determination was issued by the United States International Trade Commission (“ITC”) in a case brought by Allergan and Medytox against Evolus, asserting that Evolus stole certain trade secrets to develop Jeuveau™. The ITC Judge determined that the Company misappropriated the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.
As a result, the ITC Judge recommended a ten-year long ban on the Company’s ability to import Jeuveau™ into the United States and a ten-year-long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.
On this news, the Company’s share price declined materially, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020.
Investors Who Have Held Evolus Stock Since May 20, 2019 May Have Legal Claims
If you have held Evolus stock since May 20, 2019, please contact Kehoe Law Firm, P.C., Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, confidential consultation and no-obligation evaluation of potential legal claims.
